Systemic treatment with a selective TNFR2 agonist alters the central and peripheral immune responses and transiently improves functional outcome after experimental ischemic stroke
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 12.2 MB, PDF document
Ischemic stroke often leaves survivors with permanent disabilities and therapies aimed at limiting detrimental inflammation and improving functional outcome are still needed. Tumor necrosis factor (TNF) levels increase rapidly after ischemic stroke, and while signaling through TNF receptor 1 (TNFR1) is primarily detrimental, TNFR2 signaling mainly has protective functions. We therefore investigated how systemic stimulation of TNFR2 with the TNFR2 agonist NewSTAR2 affects ischemic stroke in mice. We found that NewSTAR2 treatment induced changes in peripheral immune cell numbers and transiently affected microglial numbers and neuroinflammation. However, this was not sufficient to improve long-term functional outcome after stroke in mice.
Original language | English |
---|---|
Article number | 578246 |
Journal | Journal of Neuroimmunology |
Volume | 385 |
Number of pages | 17 |
ISSN | 0165-5728 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023 The Authors
- Cytokines, Ischemic stroke, Microglia, Neuroinflammation, Peripheral immune cells, TNFR2 agonist
Research areas
ID: 374665936